Evidence map›Paper›PMID 40506443›Full record

ArticleNPJ biofilms and microbiomes2025

Gut microbiota alterations are linked to COVID-19 severity in North African and European populations.

Marius Bredon, Pierre Hausfater, Loubna Khalki, Youssef Tijani, Amine Cheikh, Loic Brot, Laura Creusot, Nathalie Rolhion, Francois Trottein, Gérard Lambeau and 11 more

Abstract read
In one paragraph

Article in NPJ biofilms and microbiomes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Gut microbial allies and adversaries in SARS-CoV-2 infection.Current research in microbial sciences · 2026
    Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Marius BredonSorbonne Université, INSERM, Centre de Recherche Saint-Antoine, CRSA, AP-HP, Saint-Antoine Hospital, Gastroenterology Department, Paris, France.
Pierre HausfaterSorbonne Université, Inserm, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France.
Loubna KhalkiFaculty of Medicine, Mohammed VI University of Health Sciences (UM6SS), Casablanca, Morocco.
Youssef TijaniFaculty of Medicine, Mohammed VI University of Health Sciences (UM6SS), Casablanca, Morocco.
Amine CheikhFaculty of Pharmacy, Abulcasis University of Health Sciences, Cheikh Zaïd Hospital, Rabat, Morocco.
Loic BrotSorbonne Université, INSERM, Centre de Recherche Saint-Antoine, CRSA, AP-HP, Saint-Antoine Hospital, Gastroenterology Department, Paris, France.
Laura CreusotSorbonne Université, INSERM, Centre de Recherche Saint-Antoine, CRSA, AP-HP, Saint-Antoine Hospital, Gastroenterology Department, Paris, France.
Nathalie RolhionSorbonne Université, INSERM, Centre de Recherche Saint-Antoine, CRSA, AP-HP, Saint-Antoine Hospital, Gastroenterology Department, Paris, France.
Francois TrotteinCentre d'Infection et d'Immunité de Lille, INSERM U1019, CNRS UMR 9017, University of Lille CHU Lille-Institut Pasteur de Lille, Lille, France.
Gérard LambeauInstitut de Pharmacologie Moléculaire et Cellulaire, Centre National de la Recherche Scientifique, Université Côte d'Azur, Valbonne, France.
Sophie Georgin-LavialleSorbonne Université, INSERM, Centre de Recherche Saint-Antoine, CRSA, AP-HP, Saint-Antoine Hospital, Gastroenterology Department, Paris, France.
Alexandre BleibtreuGut, Liver & Microbiome Research (GLIMMER) FHU, Paris, France.
Jean-Luc BaudelService de Médecine Intensive - Réanimation, Hôpital Saint-Antoine, Paris, France.
Antoine LefèvreUMR 1253, Imagerie et Cerveau, Tours, France.
Patrick EmondUMR 1253, Imagerie et Cerveau, Tours, France.
Florence TubachSorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP, Hôpital Pitié Salpêtrière, Département de Santé Publique, Centre de Pharmacoépidémiologie (Cephepi), Unité de Recherche Clinique PSL-CFX, Paris, France.
Noémie Simon-TillauxSorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP, Hôpital Pitié Salpêtrière, Département de Santé Publique, Centre de Pharmacoépidémiologie (Cephepi), Unité de Recherche Clinique PSL-CFX, Paris, France.
Tabassome SimonGut, Liver & Microbiome Research (GLIMMER) FHU, Paris, France.
Guy GorochovGut, Liver & Microbiome Research (GLIMMER) FHU, Paris, France.
Younes ZaidFaculty of Pharmacy, Abulcasis University of Health Sciences, Cheikh Zaïd Hospital, Rabat, Morocco.
Harry SokolSorbonne Université, INSERM, Centre de Recherche Saint-Antoine, CRSA, AP-HP, Saint-Antoine Hospital, Gastroenterology Department, Paris, France. harry.sokol@gmail.com.

Funding

AAP générique 2022 ANR-23-CE15-0014-01, GUTSYBalvi Filantropic Fund PR-BLV-20220527DIM One Health 2020 RPH20003DDP
6 · The paper itself

Abstract

Although COVID-19 primarily affects the respiratory system, many patients experience gastrointestinal symptoms, suggesting a role for the gut microbiota in disease pathogenesis. To explore this, we performed shotgun metagenomic sequencing on stool samples from 200 COVID-19 patients and 102 healthy controls in Morocco and France. Despite geographic differences in microbiota composition, patients with COVID-19 in both continents exhibited significant gut microbiota alterations, which were more pronounced in severe cases, with similar features compared with controls. Functional pathways, including L-Tryptophan biosynthesis, were disrupted, particularly in patients with severe disease. Machine learning models accurately predicted disease severity based on gut microbial profiles in the Moroccan cohort, though not in the French cohort. These results highlight consistent microbiota changes associated with COVID-19 and support a potential link between gut dysbiosis and disease severity.

Indexed as

COVID-19DysbiosisGastrointestinal MicrobiomeAdultAgedBacteriaFecesFemaleFranceHumansMaleMetagenomicsMiddle AgedMoroccoNorth African PeopleSeverity of Illness Index

Identifiers

PMID40506443
PMCPMC12163079

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.